Table 9.
CEA (Original year of values) | Treatment vs. Comparator | ICER summary/estimate [2013 US$] | Unit of effectiveness | Incremental cost [2013 US$] | Incremental effectiveness |
---|---|---|---|---|---|
Abidia 2003 (2000) [48] | HBOT vs. control | Dominant | Additional wound healed | −7,596 | 0.625 |
Apelqvist 1996 (1993) [49] | Cadexomer iodine ointment vs. standard treatment | Dominanta | Additional wound healed | −119 | 0.183 |
Edmonds 1999 (1996) [50] | Filgrastim vs. placebo | Dominanta,b | Hospital-free day gained | −7,738 | 7.5 |
Guo 2003 (2001) [51] | HBOT + SC vs. SC alone | 3508a | QALY gained | 2,137 | 0.609 |
Habacher 2007 (2001) [52] | Intensified treatment vs. SC | Dominanta | Patient-year gained | −7,625 | 2.97 |
Horswell 2003 (1999) [53] | Staged management diabetes foot program vs. SC | Dominanta | Foot-related hospitalization avoided | −7,848 | 0.41 |
Jansen 2009 (2006) [54] | Ertapenem vs. Piperacillin/Tazobactam | Dominanta | Lifetime QALY gained | −822 | 0.12 |
Jeffcoate 2009c (2007) [55] | Hydrocolloid (Aquacel) vs. antiseptic (Inadine) | 1449a | Additional wound healed | 14 | 0.01 |
Jeffcoate 2009c (2007) [55] | Antiseptic (Inadine) vs. non-adherent dressing | 1590a | Additional wound healed | 80 | 0.05 |
McKinnon 1997 (1994) [56] | Ampicillin/sulbactam vs. imipenem/cilastatin | Dominanta | Hospitalization day avoided | −5,891 | 3.5 |
Persson 2000 (1999) [57] | Becaplermin plus GWC (unspecified) vs. GWC alone | Dominanta | Ulcer-free month gained | −628 | 0.81 |
Piaggesi 2007 (2006) [58] | Total contact casting vs. Optima Diab device | 8,578 | Additional wound healed | 858 | 0.1 |
Redekop 2003 (1999) [59] | Apligraf (skin substitute) + GWCd vs. GWC alone | Dominanta | Ulcer-free month gained | −1,223 | 1.53 |
Allenet 2000 (1998) [60] | Dermagraft (human dermal replacement) vs. SC | 70,961a | Additional wound healed | 12,652 | 0.178 |
Ghatnekar 2002 (2000) [61] | Promogran dressing plus GWCe vs. GWC alone | Dominanta | Additional wound healed | −294 | 0.042 |
Ghatnekar 2001 (1999) [62] | Becaplermin gel (containing recombinant human platelet-derived growth factor) plus GWCf vs. GWC alone | Dominanta | Ulcer-free month gained | −794 | 0.81 |
Hailey 2007 (2004) [63] | HBOT + SC vs. SC alone | Dominant | QALY gained | −9,337 | 0.63 |
GWC, Good wound care; HBOT, Hyperbaric oxygen therapy; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year; SC, Standard care; US$, United States dollars.
aDenotes the higher quality studies (Drummond score ≥8).
b“Patient selection may have occurred during the in-hospital stay where more control patients experienced a bad vascular condition requiring the more costly interventions”.
cMultiple comparisons are reported.
dGWC, “the best wound care available and consists mainly of offloading, debridement, and moist dressings”.
eGWC, “sharp debridement (if necessary) and wound cleansing. In the GWC alone arm, the primary dressing was saline-soaked gauze and the secondary gauze and tape”.
fGWC, “sharp debridement to remove callus, fibrin and necrotic tissue; moist saline dressing changes every 12 hours; systematic control of infection, if present; glucose control; and offloading of pressure”.